MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-ß receptor 2 in gastric cancer

Oncotarget

Volumn 7, Issue 22, 2016, Pages 33286-33296

  Qu, Yanjun ^a   Zhang, Haiyang ^a   Duan, Jingjing ^a   Liu, Rui ^a   Deng, Ting ^a   Bai, Ming ^a   Huang, Dingzhi ^a   Li, Hongli ^a   Ning, Tao ^a   Zhang, Le ^a   Wang, Xia ^a   Ge, Shaohua ^a   Zhou, Likun ^a   Zhong, Benfu ^a   Ying, Guoguang ^a   Ba, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Gastric cancer; Migration; MiR 17 5p; TGFBR2

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 17 5P; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; MIRN17 MICRORNA, HUMAN; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; CANCER TISSUE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GASTRIC CANCER CELL LINE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PLASMID; PROTEIN TARGETING; RNA BINDING; RNA INTERFERENCE; SGC 7901 CELL LINE; STOMACH CANCER; STOMACH CARCINOGENESIS; TRANSCRIPTION REGULATION; UPREGULATION; BINDING SITE; BIOLOGY; CELL MOTION; DOWN REGULATION; GENETIC DATABASE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84973571869     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8946     Document Type: Article

References (36)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015; 136:E359-386.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
3. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
4. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C. MicroRNA profiling of human gastric cancer. Molecular medicine reports. 2009; 2:963-970.
5. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature reviews Genetics. 2004; 5:522-531.
6. Bushati N, Cohen SM. microRNA functions. Annual review of cell and developmental biology. 2007; 23:175-205.
7. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005; 436:214-220.
8. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature reviews Genetics. 2008; 9:102-114.
9. Friedman JM, Jones PA. MicroRNAs: critical mediators of differentiation, development and disease. Swiss medical weekly. 2009; 139:466-472.
10. McManus MT. MicroRNAs and cancer. Seminars in cancer biology. 2003; 13:253-258.
11. Eder M, Scherr M. MicroRNA and lung cancer. The New England journal of medicine. 2005; 352:2446-2448.
12. Li X, Zhang Z, Yu M, Li L, Du G, Xiao W, Yang H. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). International journal of molecular sciences. 2013; 14:16226-16239.
13. Li H, Xie S, Liu X, Wu H, Lin X, Gu J, Wang H, Duan Y. Matrine alters microRNA expression profiles in SGC- 7901 human gastric cancer cells. Oncology reports. 2014; 32:2118-2126.
14. Riquelme I, Tapia O, Leal P, Sandoval A, Varga MG, Letelier P, Buchegger K, Bizama C, Espinoza JA, Peek RM, Araya JC, Roa JC. miR-101-2, miR-125b-2 and miR- 451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cellular oncology (Dordrecht). 2015.
15. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. Journal of the National Cancer Institute. 2000; 92:1388-1402.
16. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes & development. 1994; 8:133-146.
17. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 1998; 95:779-791.
18. Cheng X, Gao W, Dang Y, Liu X, Li Y, Peng X, Ye X. Both ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. Journal of diabetes research. 2013; 2013:463740.
19. Zhang L, Zhou F, ten Dijke P. Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends in biochemical sciences. 2013; 38:612-620.
20. Hamzeh MT, Sridhara R, Alexander LD. Cyclic stretchinduced TGF-beta1 and fibronectin expression is mediated by beta1-integrin through c-Src- and STAT3-dependent pathways in renal epithelial cells. American journal of physiology Renal physiology. 2015; 308:F425-436.
21. Li C, Wang Q, Wang JF. Transforming growth factor-beta (TGF-beta) induces the expression of chondrogenesisrelated genes through TGF-beta receptor II (TGFRII)- AKT-mTOR signaling in primary cultured mouse precartilaginous stem cells. Biochemical and biophysical research communications. 2014; 450:646-651.
22. Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, Huang T, Sun LZ. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene. 2014; 33:4097-4106.
23. de Miranda NF, van Dinther M, van den Akker BE, van Wezel T, ten Dijke P, Morreau H. Transforming Growth Factor beta Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2. Gastroenterology. 2015; 148:1427-1437.e1428.
24. Wang JL, Hu Y, Kong X, Wang ZH, Chen HY, Xu J, Fang JY. Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. PloS one. 2013; 8:e73683.
25. Li H, Cheng J, Mao Y, Jiang M, Fan X. miR-21 inhibits the effects of cyclooxygenase-2 inhibitor NS398 on apoptosis and invasion in gastric cancer cells. OncoTargets and therapy. 2015; 8:3245-3253.
26. Li L, Zhou L, Li Y, Lin S, Tomuleasa C. MicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell deathprotein 4 and phosphatase and tensin homolog. Journal of BUON. 2014; 19:228-236.
27. Naito Y, Sakamoto N, Oue N, Yashiro M, Sentani K, Yanagihara K, Hirakawa K, Yasui W. MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer. Cancer science. 2014; 105:228-235.
28. Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, Tian DA, Zhang P. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World journal of gastroenterology. 2013; 19:7758-7765.
29. Zhuang M, Shi Q, Zhang X, Ding Y, Shan L, Shan X, Qian J, Zhou X, Huang Z, Zhu W, Ding Y, Cheng W, Liu P, Shu Y. Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Tumour biology. 2015; 36:2737-2745.
30. Zhang Z, Liu S, Shi R, Zhao G. miR-27 promotes human gastric cancer cell metastasis by inducing epithelialto- mesenchymal transition. Cancer genetics. 2011; 204:486-491.
31. Liu L, Zou J, Wang Q, Yin FQ, Zhang W, Li L. Novel microRNAs expression of patients with chemotherapy drugresistant and chemotherapy-sensitive epithelial ovarian cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:7713-7717.
32. Palmieri C, Cleator S, Kilburn LS, Kim SB, Ahn SH, Beresford M, Gong G, Mansi J, Mallon E, Reed S, Mousa K, Fallowfield L, Cheang M, Morden J, Page K, Guttery DS, et al. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast cancer research and treatment. 2014; 148:581-590.
33. Sun Z, Song X, Li X, Su T, Qi S, Qiao R, Wang F, Huan Y, Yang W, Wang J, Nie Y, Wu K, Gao M, Cao F. In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. Nanoscale. 2014; 6:14343-14353.
34. Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, Viktorsson K, Zhivotovsky B. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. British journal of cancer. 2012; 107:1361-1373.
35. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine & growth factor reviews. 1996; 7:93-102.
36. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113:685-700.